Exact Sciences Corp., founded in the United States, is dedicated to developing non-invasive molecular screening tests for early cancer detection, with a primary focus on colorectal cancer. Their flagship product, a stool-based DNA test, identifies genetic mutations associated with pre-cancer and cancer cells, aiming to catch the disease at its earliest stages. The company's vision is to eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment, thereby improving patient outcomes and saving lives.

Notable figures affiliated with Exact Sciences include key researchers and medical professionals who have contributed to the development of their innovative diagnostic tools. The company has garnered significant investment and support from the healthcare sector, reflecting confidence in its mission and technology. Key achievements include the successful commercialization of their colorectal cancer screening test and ongoing advancements in their diagnostic pipeline. Exact Sciences has made a substantial impact on cancer detection and prevention, positioning itself as a leader in the field of molecular diagnostics.